The 42nd JP Morgan Healthcare Conference is set to take place from Jan. 8 to 11 in San Francisco, California, in the U.S. This annual event, held every January, is renowned as the world’s largest healthcare investment venue where major global pharmaceutical companies, emerging biotech firms, and professional investors converge to share the latest research and development trends and forge investment and partnership opportunities.
This year, six South Korean companies have been officially invited by JP Morgan to present their business strategies to global investors, an increase of three from the previous year. These companies include Samsung Biologics, Celltrion, SK biopharm, Yuhan Corporation, Kakao Healthcare, and Lotte Biologics. Among them, Samsung Biologics and Celltrion have earned the opportunity to present on the main track session stage, while the remaining four will showcase their mid-to-long-term strategies and visions in the Asia-Pacific (APA) session.
Samsung Biologics, participating for the eighth consecutive year, and Celltrion, returning after four years, will take to the main track presentation stage. John Rim, CEO of Samsung Biologics, is scheduled to speak on Jan. 9 (local time), focusing on the theme “Leap Forward, Beyond the Reach of the Past.” He will discuss Samsung Biologics’ key achievements in 2023, outlook for 2024, and its mid-to-long-term vision.
On Jan. 10 (local time), the newly merged Integrated Celltrion, combining Celltrion and Celltrion Pharm, is expected to outline its key business strategies. Yuhan Corporation will present its strategy centered on the lung cancer drug Leclaza in the Asia-Pacific track. SK biopharm is anticipated to promote its epilepsy drug Cenobamate, which has been launched in the U.S. Lotte Biologics plans to discuss its operational plans for its Syracuse, New York plant and the development of its Bioplant in Songdo, Incheon. Lastly, Kakao Healthcare is set to introduce its smartphone-based blood sugar management platform PASTA, slated for release in February, to investors.